依普利酮适合什么人服用？

Who is it suitable for? Eplerenone, whose English name is Inspra, is the first selective aldosterone receptor blocker approved for marketing. It was approved for marketing in the United States in 2002. Its indications are for the treatment of congestive heart failure after acute myocardial infarction and the treatment of patients with hypertension.

The initial dose of eplerenone for the treatment of congestive heart failure is 25 mg orally once daily; the dose can be increased to the target dose within four weeks as tolerated by the patient. The target dose is 50 mg orally once daily.

When treating adult patients with hypertension, eplerenone (Inspra) can be used alone or in combination with other antihypertensive drugs. It is administered orally. The initial dose is 50 mg, once a day; the maintenance dose is 50 mg, 1-2 times a day. The maximum dose is 100 mg/day and patients should not overdose. Typically, significant blood pressure lowering effects occur within four weeks of taking eplerenone. Patients whose blood pressure responds inadequately to the initial dose may be increased to 50 mg twice daily.

Untreated hypertension and heart failure are both associated with adverse pregnancy outcomes. The use of mineralocorticoid receptor antagonists is not recommended for the treatment of chronic isolated hypertension in pregnant women and should generally be avoided in women of reproductive potential.

In the study, it was found that patients with severe hypertension may have difficulty controlling the combination of multiple antihypertensive drugs, but the addition of eplerenone (Inspra) can significantly reduce the patient's blood pressure, especially the systolic blood pressure. Combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve patients' quality of life and reduce mortality in severe heart failure and myocardial infarction.

The above is an introduction to the indications and applicable methods. I hope it will be helpful to you.